BCM
CTNM

Bridgeway Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Bridgeway Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$808K Hold
49,280
– – 0.01% 776
2026
Q1 		$644K Hold
49,280
– – 0.01% 781
2025
Q4 		$563K Buy
49,280
+7,700
+19% +$87.9K 0.01% 796
2025
Q3 		$489K Buy
41,580
+22,380
+117% +$180K 0.01% 810
2025
Q2 		$76.2K Buy
+19,200
New +$83.4K ﹤0.01% 1102

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bridgeway Capital Management's CTNM Position: Q2 2026 in Review

Bridgeway Capital Management held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 49,280 shares worth $808K. The position accounts for 0.01% of the portfolio, ranked #776.

Bridgeway Capital Management first reported a position in CTNM in Q2 2025 and has held it in 5 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Bridgeway Capital Management held 49,280 shares of Contineum Therapeutics worth $808K as of Q2 2026.
  • Bridgeway Capital Management left its Contineum Therapeutics share count unchanged in Q2 2026.
  • Contineum Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #776 holding.
  • Bridgeway Capital Management first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.